Australia is experience potentially transformative treatment for excess weight: Retatrutide. This new dual agonist – working on both GLP-1 and GIP receptors – demonstrates promising efficacy in global studies, pointing to meaningful decreases in BMI. While regulatory clearance remains with Australian regulators, several Australians dealing with